Chen group | Immunogenomics in Autoimmunity and Cancer
Genetic studies have identified many genetic risks affecting the chance of developing inflammatory diseases or cancers. Only a small minority of these findings have been translated to new knowledge or treatment options, partially due to inter-discipline barriers between Genetics and Immunology.
We would like to overcome these barriers through a unique strategy of integrating datasets from genetic and immunological studies for the goal discovering novel immune regulators and drug targets in human diseases.
Key areas of interests
- Identification and validation of novel drug targets in inflammatory arthritis.
- Interrogating the immune regulations by the genetic risks shared across common human diseases.
- Leveraging genetics to discover common immune pathways key for both autoimmune diseases and cancer.